Targeting GAS6-AXL Pathfly Idea Di Pharmaceuticals has been exclusively licensed as a new cancer drug in Greater China

AXL is one of the genes that encodes the lipolyst tyrosine kinase, and its ligation GAS6 (growth arrest-specific gene 6) is highly expressed and active in many malignant tumors, such as acute myeloid leukemia, kidney cancer, pancreatic cancer, breast cancer, lung cancer and ovarian cancer.
GAS6-AXL signaling path, as one of the key path pathraps to promote tumor growth and metastasis, tumor immune escape and drug tolerance, is considered to be a new target for cancer treatment and has attracted wide attention.
in addition, studies have shown that GAS6-AXL signaling pathline inhibitors can be used in combination with immunotherapy checkpoint inhibitors, radiotherapy or chemotherapy to achieve good tumor control.
, gas6-AXL signaling path has become one of the most important breakthroughs in the field of tumor therapy.
As a recombinant fusion protein targeting the GAS6-AXL path pathrain, the AVB-500 has been shown in preclinical studies to neutralize its activity by binding gas6 to selectively inhibit the signaling path.
clinical studies of the drug are still ongoing and have been awarded fast-track status by the FDA for platinum-resistant relapsed ovarian cancer adaptation.
addition, the AVB-500 is generally well-to-do and does not see dose-limiting toxicity or unexpected safety signals.
that Aravive has successfully completed the AVB-500 phase 1b clinical trial of platinum-resistant ovarian cancer adaptation in the United States and is about to enter Phase 3 registered clinical studies.
same time, a number of clinical studies have been conducted on multiple adaptations such as transparent cell renal cell carcinoma.
For this authorization, Wedi Pharmaceuticals also pointed out that this is the introduction of RMX1001 and RMX1002 two new analgesic drugs from Haihe Pharmaceuticals in October 2020, the company in response to the trend of slow tumor disease, further build through the tumor immunotherapy full-cycle pipeline layout of another important initiative.
Ofid pharma has been authorized for exclusive development and commercialization of the NASDAQ-listed Aravive anti-cancer drug AVB-500 Greater China. Retrieved Nov 11, 2020, From Source: Medical Mission Hills